会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • POST-TREATMENT BREAST CANCER PROGNOSIS
    • 治疗后乳腺癌预后
    • US20130281502A1
    • 2013-10-24
    • US13914617
    • 2013-06-10
    • Dennis SgroiMark G. ErlanderYi ZhangCatherine A. Schnabel
    • Dennis SgroiMark G. ErlanderYi ZhangCatherine A. Schnabel
    • C12Q1/68
    • C12Q1/6886C12Q2600/106C12Q2600/118C12Q2600/158
    • The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis.
    • 该公开内容包括鉴定和使用基因表达谱或模式,其与患者中延长的治疗和无癌生存具有临床相关性。 具体地,本公开包括与用于治疗患者的内分泌治疗的转换中的益处相关表达的基因的身份。 公开了基因表达水平作为预测临床结果的分子指标,并为患者预后。 本发明还包括在用抗雌激素剂初次治疗后预测癌症复发和/或预测转移性癌症的发生的方法。 本公开还包括基于预期寿命,癌症复发和/或癌症转移的可能性来确定或选择受试者的治疗的方法。
    • 8. 发明申请
    • TUMOR GRADING AND CANCER PROGNOSIS
    • 肿瘤分级和癌症预后
    • US20110136680A1
    • 2011-06-09
    • US12718973
    • 2010-03-06
    • Mark G. ErlanderXiao-Jun MaDennis Sgroi
    • Mark G. ErlanderXiao-Jun MaDennis Sgroi
    • C12Q1/68C40B30/00
    • C12Q1/6886C12Q2600/106C12Q2600/112
    • The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to cancer. In particular, the disclosure includes the identities of genes that are expressed in correlation with tumor grade. The levels of gene expression are disclosed as a molecular index for determining tumor grade in a patient and predicting clinical outcome, and so prognosis, for the patient. The molecular grading of cancer may optionally be used in combination with a second molecular index for diagnosing cancer and its prognosis. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer. For diagnosis or prognosis, the disclosure further includes methods for determining or selecting the treatment of cancer based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis.
    • 该公开内容包括鉴定和使用与癌症具有临床相关性的基因表达谱或模式。 特别地,本公开包括与肿瘤等级相关表达的基因的身份。 公开了基因表达水平作为确定患者肿瘤分级的分子指标,并预测了患者的临床结果以及预后。 癌症的分子分级可以任选地与用于诊断癌症及其预后的第二分子指数组合使用。 本公开还包括用于预测癌症复发和/或预测转移性癌症发生的方法。 为了诊断或预后,本公开还包括基于预期寿命,癌症复发和/或癌症转移的可能性来确定或选择癌症治疗的方法。